The Cardiovascular Sciences Small Business Activities Special Emphasis Panel reviews small business grant applications related to the general areas of cardiac and circulatory system devices, therapies and diagnostics. Projects are included at all levels of organization ranging from in vitro cell and tissue model systems through whole organisms, including humans. The stages of product development include technologies that have a prototype in-hand, through to the clinical research stage.
As 2023/01 this SBIR/STTR SEP has been combined with the Small Business: Vascular and Hematology SEP and is now VH(10) Cardiovascular and Hematological Sciences Small Business Special Emphasis Panel.
- Cardiology, cardiac function, heart failure, myocardial ischemia, reperfusion injury, stents, thrombosis/thrombolysis, imaging, monitoring systems
- Electrophysiology, arrhythmias, sudden death, pacing, arrhythmia ablation
- Cardiac and vascular surgery
- Cell therapy and novel approaches to tissue repair/regeneration
- Emergency medicine, resuscitation, laboratory medicine, clinical chemistry, biomarkers
- Lipid disorders, atherosclerosis
- Biomedical and tissue engineering, biomaterials
- Gene therapy and gene delivery systems
- Pharmacology, physiology
Shared Interests and Overlaps
VH-11 and Medical Imaging (SBIB-10)have shared interests in topics related to medical imaging technologies. Applications which utilize established or newly developed imaging strategies applied within the context of cardiovascular systems research may be reviewed in CVRS-10. Applications which emphasize the development of novel imaging systems or strategies may be reviewed in SBIB-10.
VH-11 and Cardiovascular and Surgical Devices (SBIB-12)have shared interests in topics related to innovative research and technology development of biomedical devices and systems; they include devices and systems designed for a variety of cardiovascular disease processes including cardiac surgery, vascular surgery/interventions, electrophysiological procedures, critical/intensive care, drug/gene therapy delivery and a variety of other innovative technologies. While SBIB-12 will review applications.